Entity Type
Company
- Info
- Portfolio
- Significant Ownership
- Insider Ownership
- Financials
- Holders: GSK, G3910J179
Filer Snapshot
Review latest filings on this page
Open reporting owner context
GSK plc SEC EDGAR Filings
SEC filings, ownership reports, and insider transactions for CIK 0001131399.
Total Filings
6,715
Latest Filing
10 Apr 2026
Industry
Pharmaceutical Preparations
Save this filer and follow what changes next
Save this research page, return after the next filing cycle, and verify details directly from SEC source links.
Save this research and follow filing changes
Create a free account to save this filer, follow filing activity, and return when something changes.
- Symbol
- GSK on NYSE, GLAXF on OTC
- Business address
- 79 New Oxford Street, London, WC1A 1DG
- Top holdings (ownership)
- WVE, LYEL, CVRX, and SPRO
- Top securities (13F)
- WVE, CRSP, BNTX, VIR, LYEL, IDYA, CYTK, SPRO, FULC, BCYC, CVRX, NKTX, RGNX, SENS, and HBIO
- Top holdings (Schedule 13D)
- CVAC and SPRO
- State of incorporation
- United Kingdom
- Former names
- GLAXOSMITHKLINE PLC (to 16 May 2022)
Quick Takeaways
- GSK plc is an SEC filer tracked under CIK 0001131399.
- 6,715 filings are listed on this profile.
- Common form coverage includes 6-K, IRANNOTICE, 20-F and more.
What Changed
- Latest filing: 6-K filed on 10 Apr 2026.
- Report period: 10 Apr 2026.
Why This Matters
- You can quote filing dates and form types directly from the SEC record on this page.
- Use this profile before deeper ownership or insider analysis to confirm filing history context.
Official SEC Source
Filer Overview
GSK plc has filed 6,715 SEC EDGAR filings since 12 Jan 2001. Common forms include 6-K, IRANNOTICE, 20-F, SC TO-T/A and more.
Latest Filings
Recent SEC filings for GSK plc with direct links to document and filing folders.
| Form type | Document | Filing | Description | Filing date | Reporting date | File number(s) |
|---|---|---|---|---|---|---|
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Apr 2026 | 10 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Apr 2026 | 10 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 Apr 2026 | 09 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 09 Apr 2026 | 09 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EXDENSUR APPROVED FOR CRSWNP IN CHINA | 08 Apr 2026 | 08 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 08 Apr 2026 | 08 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 07 Apr 2026 | 07 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 Apr 2026 | 02 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Apr 2026 | 01 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Apr 2026 | 01 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 01 Apr 2026 | 01 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDING | 01 Apr 2026 | 01 Apr 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 31 Mar 2026 | 31 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA | 30 Mar 2026 | 30 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA | 30 Mar 2026 | 30 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 30 Mar 2026 | 30 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 27 Mar 2026 | 27 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA | 27 Mar 2026 | 27 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 26 Mar 2026 | 26 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 25 Mar 2026 | 25 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 25 Mar 2026 | 25 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 25 Mar 2026 | 25 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 24 Mar 2026 | 24 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Mar 2026 | 23 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ADMISSION TO TRADING | 23 Mar 2026 | 23 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS | 23 Mar 2026 | 23 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 23 Mar 2026 | 23 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 20 Mar 2026 | 20 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNAVOY (LINERIXIBAT) APPROVED BY US FDA | 19 Mar 2026 | 19 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 19 Mar 2026 | 19 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Mar 2026 | 18 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 18 Mar 2026 | 18 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Mar 2026 | 17 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 17 Mar 2026 | 17 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 16 Mar 2026 | 16 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR | 13 Mar 2026 | 13 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 13 Mar 2026 | 13 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Mar 2026 | 12 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 12 Mar 2026 | 12 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 11 Mar 2026 | 11 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Mar 2026 | 10 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD COMMITTEE CHANGE | 09 Mar 2026 | 09 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS | 09 Mar 2026 | 09 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 09 Mar 2026 | 09 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F | 06 Mar 2026 | 06 Mar 2026 | 001-15170 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 06 Mar 2026 | 001-15170 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | 20-F | 06 Mar 2026 | 31 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 06 Mar 2026 | 06 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PUBLISHES ANNUAL REPORT 2025 | 05 Mar 2026 | 05 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 05 Mar 2026 | 05 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 04 Mar 2026 | 04 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 04 Mar 2026 | 04 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS | 03 Mar 2026 | 03 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 03 Mar 2026 | 03 Mar 2026 | 001-15170 |
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T/A | 03 Mar 2026 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 Mar 2026 | 02 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Mar 2026 | 02 Mar 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 27 Feb 2026 | 27 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 27 Feb 2026 | 27 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA | 26 Feb 2026 | 26 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW | 26 Feb 2026 | 26 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 26 Feb 2026 | 26 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 25 Feb 2026 | 25 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 25 Feb 2026 | 25 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA | 25 Feb 2026 | 25 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 25 Feb 2026 | 25 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 24 Feb 2026 | 24 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 24 Feb 2026 | 24 Feb 2026 | 001-15170 |
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T/A | 24 Feb 2026 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 23 Feb 2026 | 23 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Feb 2026 | 20 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 20 Feb 2026 | 20 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Feb 2026 | 19 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 19 Feb 2026 | 19 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 18 Feb 2026 | 18 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2026 | 17 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2026 | 17 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMME | 17 Feb 2026 | 17 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | 17 Feb 2026 | 17 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2026 | 17 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2026 | 17 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2026 | 17 Feb 2026 | 001-15170 |
| 13F-HR | Open 13F-HR document | View SEC filing for 13F-HR | 12 Feb 2026 | 31 Dec 2025 | 028-26280 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Feb 2026 | 11 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Feb 2026 | 11 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Feb 2026 | 11 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Feb 2026 | 11 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION | 10 Feb 2026 | 10 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 Feb 2026 | 09 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Feb 2026 | 06 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION | 06 Feb 2026 | 06 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 05 Feb 2026 | 05 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL RESULTS | 04 Feb 2026 | 04 Feb 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Feb 2026 | 02 Feb 2026 | 001-15170 |
| SC TO-T | Open SC TO-T document | Open XBRL data | View SEC filing for SC TO-T | SC TO-T | 02 Feb 2026 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ | 26 Jan 2026 | 26 Jan 2026 | 001-15170 |
| SC TO-C | Open SC TO-C document | View SEC filing for SC TO-C | SC TO-C | 20 Jan 2026 | ||
| SC TO-C | Open SC TO-C document | View SEC filing for SC TO-C | SC TO-C | 20 Jan 2026 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK TO ACQUIRE RAPT THERAPEUTICS | 20 Jan 2026 | 20 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING | 20 Jan 2026 | 20 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Jan 2026 | 16 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Jan 2026 | 15 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Jan 2026 | 13 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EC APPROVAL OF SHINGRIX PFS | 07 Jan 2026 | 07 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN | 07 Jan 2026 | 07 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EXDENSUR APPROVED IN JAPAN | 06 Jan 2026 | 06 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 05 Jan 2026 | 05 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 05 Jan 2026 | 05 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA | 05 Jan 2026 | 05 Jan 2026 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US | 23 Dec 2025 | 23 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Dec 2025 | 22 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 22 Dec 2025 | 22 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 19 Dec 2025 | 19 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 18 Dec 2025 | 18 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA | 17 Dec 2025 | 17 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 17 Dec 2025 | 17 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL | 16 Dec 2025 | 16 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 16 Dec 2025 | 16 Dec 2025 | 001-15170 |
| 4 | Open 4 document | View SEC filing for 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | 15 Dec 2025 | 11 Dec 2025 | 001-37627 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 15 Dec 2025 | 15 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION | 12 Dec 2025 | 12 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD | 12 Dec 2025 | 12 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ | 12 Dec 2025 | 12 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 12 Dec 2025 | 12 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION | 11 Dec 2025 | 11 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Dec 2025 | 11 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING APPLICATION | 11 Dec 2025 | 11 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 11 Dec 2025 | 11 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Dec 2025 | 10 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLC | 10 Dec 2025 | 10 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 Dec 2025 | 09 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 09 Dec 2025 | 09 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 08 Dec 2025 | 08 Dec 2025 | 001-15170 |
| SCHEDULE 13D/A | Open SCHEDULE 13D/A document | View SEC filing for SCHEDULE 13D/A | 05 Dec 2025 | |||
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 05 Dec 2025 | 05 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 04 Dec 2025 | 04 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 03 Dec 2025 | 03 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 Dec 2025 | 02 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Dec 2025 | 01 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Dec 2025 | 01 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 01 Dec 2025 | 01 Dec 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 28 Nov 2025 | 28 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 28 Nov 2025 | 28 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 26 Nov 2025 | 26 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 25 Nov 2025 | 25 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 24 Nov 2025 | 24 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | INITIATION OF LITIGATION AGAINST ANAPTYSBIO INC | 21 Nov 2025 | 21 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 21 Nov 2025 | 21 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 20 Nov 2025 | 20 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSFER OF TREASURY SHARES | 19 Nov 2025 | 19 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 19 Nov 2025 | 19 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Nov 2025 | 18 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 18 Nov 2025 | 18 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 17 Nov 2025 | 17 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 14 Nov 2025 | 14 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Nov 2025 | 13 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 13 Nov 2025 | 13 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 12 Nov 2025 | 12 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 12 Nov 2025 | 12 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 12 Nov 2025 | 12 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PUBLISHES PROVISIONAL DIVIDEND DATES | 10 Nov 2025 | 10 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Nov 2025 | 10 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 07 Nov 2025 | 07 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 06 Nov 2025 | 06 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 05 Nov 2025 | 05 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 04 Nov 2025 | 04 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Nov 2025 | 03 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 03 Nov 2025 | 03 Nov 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 31 Oct 2025 | 31 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 30 Oct 2025 | 30 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 30 Oct 2025 | 30 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 29 Oct 2025 | 29 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 3RD QUARTER RESULTS | 29 Oct 2025 | 29 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 28 Oct 2025 | 28 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU | 28 Oct 2025 | 28 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 27 Oct 2025 | 27 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA | 24 Oct 2025 | 24 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 24 Oct 2025 | 24 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 23 Oct 2025 | 23 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI | 22 Oct 2025 | 22 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 22 Oct 2025 | 22 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LATOZINEMAB DATA READ OUT | 22 Oct 2025 | 22 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS | 21 Oct 2025 | 21 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 21 Oct 2025 | 21 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR | 21 Oct 2025 | 21 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 20 Oct 2025 | 20 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 17 Oct 2025 | 17 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Oct 2025 | 16 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 16 Oct 2025 | 16 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Oct 2025 | 15 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 15 Oct 2025 | 15 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA | 14 Oct 2025 | 14 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 14 Oct 2025 | 14 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Oct 2025 | 14 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 14 Oct 2025 | 14 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Oct 2025 | 10 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Oct 2025 | 10 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 09 Oct 2025 | 09 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 08 Oct 2025 | 08 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 07 Oct 2025 | 07 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 06 Oct 2025 | 06 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 03 Oct 2025 | 03 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 Oct 2025 | 02 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Oct 2025 | 01 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 01 Oct 2025 | 01 Oct 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK - THIRD TRANCHE OF SHARE BUYBACK PROGRAMME | 30 Sep 2025 | 30 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK APPOINTS CEO DESIGNATE | 29 Sep 2025 | 29 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Sep 2025 | 22 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 19 Sep 2025 | 19 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 18 Sep 2025 | 18 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK US INVESTMENT ANNOUNCEMENT | 17 Sep 2025 | 17 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 17 Sep 2025 | 17 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 16 Sep 2025 | 16 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 15 Sep 2025 | 15 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 12 Sep 2025 | 12 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 11 Sep 2025 | 11 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Sep 2025 | 10 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Sep 2025 | 10 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 09 Sep 2025 | 09 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 08 Sep 2025 | 08 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 05 Sep 2025 | 05 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 04 Sep 2025 | 04 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 04 Sep 2025 | 04 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 03 Sep 2025 | 03 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 Sep 2025 | 02 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Sep 2025 | 02 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 Sep 2025 | 02 Sep 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 29 Aug 2025 | 29 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 28 Aug 2025 | 28 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 27 Aug 2025 | 27 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 26 Aug 2025 | 26 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 22 Aug 2025 | 22 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Aug 2025 | 21 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 21 Aug 2025 | 21 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 20 Aug 2025 | 20 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Aug 2025 | 19 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 19 Aug 2025 | 19 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 18 Aug 2025 | 18 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 15 Aug 2025 | 15 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 14 Aug 2025 | 14 Aug 2025 | 001-15170 |
| SCHEDULE 13D | Open SCHEDULE 13D document | View SEC filing for SCHEDULE 13D | 13 Aug 2025 | |||
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 13 Aug 2025 | 13 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Aug 2025 | 12 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 12 Aug 2025 | 12 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA TO REVIEW GONORRHEA INDICATION FOR GEPOTIDACIN | 11 Aug 2025 | 11 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 11 Aug 2025 | 11 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CUREVAC/BIONTECH MRNA PATENT LITIGATION SETTLEMENT | 08 Aug 2025 | 08 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 08 Aug 2025 | 08 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 07 Aug 2025 | 07 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 06 Aug 2025 | 06 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 05 Aug 2025 | 05 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 04 Aug 2025 | 04 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Aug 2025 | 01 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 01 Aug 2025 | 01 Aug 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 31 Jul 2025 | 31 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 2ND QUARTER RESULTS | 30 Jul 2025 | 30 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 30 Jul 2025 | 30 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 29 Jul 2025 | 29 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ENTERS HENGRUI PHARMA COLLABORATION AGREEMENTS | 28 Jul 2025 | 28 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | PRIMARY DOCUMENT | 28 Jul 2025 | 28 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 25 Jul 2025 | 25 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLENREP APPROVED IN THE EU FOR MULTIPLE MYELOMA | 24 Jul 2025 | 24 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 24 Jul 2025 | 24 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA REVIEW EXTENDED FOR BLENREP | 23 Jul 2025 | 23 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 23 Jul 2025 | 23 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 22 Jul 2025 | 22 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 21 Jul 2025 | 21 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Jul 2025 | 18 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLENREP US ODAC OUTCOME | 18 Jul 2025 | 18 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 18 Jul 2025 | 18 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSKS SHINGRIX FULLY LIQUID FDA APPROVAL | 17 Jul 2025 | 17 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 17 Jul 2025 | 17 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 16 Jul 2025 | 16 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Jul 2025 | 15 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 15 Jul 2025 | 15 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Jul 2025 | 14 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA | 14 Jul 2025 | 14 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 14 Jul 2025 | 14 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 11 Jul 2025 | 11 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Jul 2025 | 10 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 09 Jul 2025 | 09 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 08 Jul 2025 | 08 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD | 07 Jul 2025 | 07 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 07 Jul 2025 | 07 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 07 Jul 2025 | 07 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 03 Jul 2025 | 03 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 Jul 2025 | 02 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jul 2025 | 01 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 01 Jul 2025 | 01 Jul 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 30 Jun 2025 | 30 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 27 Jun 2025 | 27 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 26 Jun 2025 | 26 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 25 Jun 2025 | 25 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 24 Jun 2025 | 24 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR DECLARATION | 24 Jun 2025 | 24 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 24 Jun 2025 | 24 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Jun 2025 | 23 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LINERIXIBAT FILE ACCEPTED BY EMA | 23 Jun 2025 | 23 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 23 Jun 2025 | 23 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AREXVY FILED IN JAPAN FOR 18-49 AT INCREASED RISK | 20 Jun 2025 | 20 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 20 Jun 2025 | 20 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 20 Jun 2025 | 20 Jun 2025 | 001-15170 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | 18 Jun 2025 | 31 Dec 2024 | 001-15170 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE PLANS | 18 Jun 2025 | 31 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 18 Jun 2025 | 18 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 17 Jun 2025 | 17 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 16 Jun 2025 | 16 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Jun 2025 | 13 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 13 Jun 2025 | 13 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA | 13 Jun 2025 | 13 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Jun 2025 | 12 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 12 Jun 2025 | 12 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Jun 2025 | 11 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 11 Jun 2025 | 11 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Jun 2025 | 10 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 09 Jun 2025 | 09 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 06 Jun 2025 | 06 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 05 Jun 2025 | 05 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK - SECOND TRANCHE OF SHARE BUYBACK PROGRAMME | 04 Jun 2025 | 04 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 04 Jun 2025 | 04 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 03 Jun 2025 | 03 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 02 Jun 2025 | 02 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Jun 2025 | 02 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LINERIXIBAT FILE ACCEPTED FOR REVIEW BY US FDA | 02 Jun 2025 | 02 Jun 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 Jun 2025 | 02 Jun 2025 | 001-15170 |
| SD | Open SD document | View SEC filing for SD | SPECIALIZED DISCLOSURE REPORT | 30 May 2025 | 001-15170 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 30 May 2025 | 30 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 29 May 2025 | 29 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK STOPS PHASE 3 TRIAL ON CUTIS FOR EFFICACY | 28 May 2025 | 28 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 28 May 2025 | 28 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 27 May 2025 | 27 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE CHMP OPINION ON BLENREP IN EU | 23 May 2025 | 23 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA APPROVES NUCALA COPD INDICATION | 23 May 2025 | 23 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 23 May 2025 | 23 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 22 May 2025 | 22 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 21 May 2025 | 21 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 May 2025 | 20 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 20 May 2025 | 20 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN | 19 May 2025 | 19 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 19 May 2025 | 19 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 16 May 2025 | 16 May 2025 | 001-15170 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 15 May 2025 | 001-15170 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 15 May 2025 | 15 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK TO ACQUIRE EFIMOSFERMIN | 14 May 2025 | 14 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 14 May 2025 | 14 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 May 2025 | 13 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON BELRESTOTUG DEVELOPMENT PROGRAMME | 13 May 2025 | 13 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 13 May 2025 | 13 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 12 May 2025 | 12 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 12 May 2025 | 12 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 09 May 2025 | 09 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 May 2025 | 08 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 May 2025 | 08 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LINERIXIBAT GLISTEN PIII TRIAL DATA AT EASL | 08 May 2025 | 08 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 08 May 2025 | 08 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 07 May 2025 | 07 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 07 May 2025 | 07 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 06 May 2025 | 06 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 May 2025 | 02 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 May 2025 | 01 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 May 2025 | 01 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NUCALA MATINEE DATA IN COPD PUBLISHED IN NEJM | 01 May 2025 | 01 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 01 May 2025 | 01 May 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 30 Apr 2025 | 30 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 1ST QUARTER RESULTS | 30 Apr 2025 | 30 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 29 Apr 2025 | 29 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 28 Apr 2025 | 28 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 25 Apr 2025 | 25 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 24 Apr 2025 | 24 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 23 Apr 2025 | 23 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 22 Apr 2025 | 22 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLENREP LICENSED BY UK MHRA | 17 Apr 2025 | 17 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Apr 2025 | 17 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AREXVY NOW ACIP RECOMMENDED FOR 50-59 AT RIS | 17 Apr 2025 | 17 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK 5-IN-1 MENINGITIS VACCINE RECOMMENDED IN US | 17 Apr 2025 | 17 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 17 Apr 2025 | 17 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 16 Apr 2025 | 16 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Apr 2025 | 15 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 15 Apr 2025 | 15 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Apr 2025 | 14 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 14 Apr 2025 | 14 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Apr 2025 | 11 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 11 Apr 2025 | 11 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Apr 2025 | 10 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 09 Apr 2025 | 09 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 08 Apr 2025 | 08 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 07 Apr 2025 | 07 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 04 Apr 2025 | 04 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 03 Apr 2025 | 03 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 02 Apr 2025 | 02 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Apr 2025 | 01 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 01 Apr 2025 | 01 Apr 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 31 Mar 2025 | 31 Mar 2025 | 001-15170 |
| SCHEDULE 13D/A | Open SCHEDULE 13D/A document | View SEC filing for SCHEDULE 13D/A | 28 Mar 2025 | |||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 28 Mar 2025 | 28 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 28 Mar 2025 | 28 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 27 Mar 2025 | 27 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 26 Mar 2025 | 26 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK UUTI TREATMENT APPROVED BY US FDA | 25 Mar 2025 | 25 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 25 Mar 2025 | 25 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 24 Mar 2025 | 24 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA FILING ACCEPTANCE FOR NUCALA COPD | 24 Mar 2025 | 24 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 24 Mar 2025 | 24 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Mar 2025 | 21 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 21 Mar 2025 | 21 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 20 Mar 2025 | 20 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 19 Mar 2025 | 19 Mar 2025 | 001-15170 |
| CERT | Open CERT document | View SEC filing for CERT | NYSE CERTIFICATION | 18 Mar 2025 | 001-15170 | |
| CERT | Open CERT document | View SEC filing for CERT | NYSE CERTIFICATION | 18 Mar 2025 | 001-15170 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 18 Mar 2025 | 18 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 17 Mar 2025 | 17 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Mar 2025 | 14 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 14 Mar 2025 | 14 Mar 2025 | 001-15170 |
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | 8-A12B | 13 Mar 2025 | 001-15170 | |
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | 8-A12B | 13 Mar 2025 | 001-15170 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | 6-K | 13 Mar 2025 | 13 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 13 Mar 2025 | 13 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 12 Mar 2025 | 12 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 11 Mar 2025 | 11 Mar 2025 | 001-15170 |
| 424B2 | Open 424B2 document | Open XBRL data | View SEC filing for 424B2 | 424B2 | 10 Mar 2025 | 333-278205 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 10 Mar 2025 | 10 Mar 2025 | 001-15170 |
| SCHEDULE 13G/A | Open SCHEDULE 13G/A document | View SEC filing for SCHEDULE 13G/A | 07 Mar 2025 | 005-84251 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 07 Mar 2025 | 07 Mar 2025 | 001-15170 |
| FWP | Open FWP document | View SEC filing for FWP | FWP | 07 Mar 2025 | 333-278205 | |
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | 424B2 | 06 Mar 2025 | 333-278205 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 06 Mar 2025 | 06 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 05 Mar 2025 | 05 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 04 Mar 2025 | 04 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PLC 2024 ANNUAL REPORT ON FORM 20-F | 03 Mar 2025 | 03 Mar 2025 | 001-15170 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 03 Mar 2025 | 001-15170 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | 20-F | 03 Mar 2025 | 31 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Mar 2025 | 03 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS | 03 Mar 2025 | 03 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANCHOR RESULTS PRESENTED AT 2025 AAAAI | 03 Mar 2025 | 03 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 03 Mar 2025 | 03 Mar 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 28 Feb 2025 | 28 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 27 Feb 2025 | 27 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PUBLISHES ANNUAL REPORT 2024 | 27 Feb 2025 | 27 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 26 Feb 2025 | 26 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 26 Feb 2025 | 26 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSACTION IN OWN SHARES | 25 Feb 2025 | 25 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES ACQUISITION OF IDRX, INC. | 24 Feb 2025 | 24 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PLC COMMENCES SHARE BUYBACK PROGRAMME | 24 Feb 2025 | 24 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 21 Feb 2025 | 21 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Feb 2025 | 21 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Feb 2025 | 21 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Feb 2025 | 21 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Feb 2025 | 21 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Feb 2025 | 21 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Feb 2025 | 21 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NUCALA COPD SUBMISSION ACCEPTED IN CHINA | 20 Feb 2025 | 20 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA | 18 Feb 2025 | 18 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Feb 2025 | 13 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Feb 2025 | 11 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL RESULTS | 05 Feb 2025 | 05 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Feb 2025 | 03 Feb 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN | 28 Jan 2025 | 28 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB | 28 Jan 2025 | 28 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION | 27 Jan 2025 | 27 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI EXPANDED APPROVAL IN THE EU | 21 Jan 2025 | 21 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Jan 2025 | 16 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Jan 2025 | 15 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Jan 2025 | 14 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Jan 2025 | 13 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. | 13 Jan 2025 | 13 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW | 10 Jan 2025 | 10 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION | 07 Jan 2025 | 07 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP | 03 Jan 2025 | 03 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Jan 2025 | 02 Jan 2025 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Dec 2024 | 23 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING APPLICATION | 20 Dec 2024 | 20 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HEADLINE RESULTS FROM PHASE III FIRST TRIAL | 20 Dec 2024 | 20 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION | 16 Dec 2024 | 16 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA GRANTS PRIME DESIGNATION FOR GSK 227 | 16 Dec 2024 | 16 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI RECEIVES POSITIVE CHMP OPINION | 16 Dec 2024 | 16 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Dec 2024 | 12 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | OVERALL SURVIVAL DATA PRESENTED FOR BLENREP | 09 Dec 2024 | 09 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLENREP COMBINATION CHINA FILING ACCEPTANCE | 09 Dec 2024 | 09 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NUCALA COPD SUBMISSION ACCEPTED BY US FDA | 09 Dec 2024 | 09 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED | 05 Dec 2024 | 05 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 02 Dec 2024 | 02 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Dec 2024 | 02 Dec 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU | 27 Nov 2024 | 27 Nov 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW | 25 Nov 2024 | 25 Nov 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 | 22 Nov 2024 | 22 Nov 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Nov 2024 | 19 Nov 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT | 19 Nov 2024 | 19 Nov 2024 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO THE SCHEDULE 13D | 15 Nov 2024 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP | 14 Nov 2024 | 14 Nov 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 13 Nov 2024 | 13 Nov 2024 | 001-15170 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | AMENDMENT TO FORM SC 13G | 12 Nov 2024 | 005-84251 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Nov 2024 | 12 Nov 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES | 12 Nov 2024 | 12 Nov 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Nov 2024 | 01 Nov 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 30 Oct 2024 | 30 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 3RD QUARTER RESULTS | 30 Oct 2024 | 30 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK | 24 Oct 2024 | 24 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Oct 2024 | 17 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Oct 2024 | 16 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN | 16 Oct 2024 | 16 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Oct 2024 | 15 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB | 15 Oct 2024 | 15 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Oct 2024 | 11 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Oct 2024 | 10 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS | 09 Oct 2024 | 09 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS | 08 Oct 2024 | 08 Oct 2024 | 001-15170 |
| 4 | Open 4 document | View SEC filing for 4 | WVE - CHANGE IN BENEFICIAL OWNERSHIP | 01 Oct 2024 | 27 Sep 2024 | 001-37627 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Oct 2024 | 01 Oct 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 24 Sep 2024 | 24 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE | 24 Sep 2024 | 24 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 18 Sep 2024 | 18 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA | 17 Sep 2024 | 17 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP | 13 Sep 2024 | 13 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Sep 2024 | 12 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA | 12 Sep 2024 | 12 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 11 Sep 2024 | 11 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CHANGE OF REGISTERED OFFICE | 11 Sep 2024 | 11 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL | 11 Sep 2024 | 11 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS | 09 Sep 2024 | 09 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Sep 2024 | 06 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE PHASE III RESULTS FOR NUCALA IN COPD | 06 Sep 2024 | 06 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Sep 2024 | 03 Sep 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA APPROVAL ON AREXVY FOR 50-59 AT RISK | 29 Aug 2024 | 29 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP | 28 Aug 2024 | 28 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN | 28 Aug 2024 | 28 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 28 Aug 2024 | 28 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Aug 2024 | 21 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Aug 2024 | 20 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION | 20 Aug 2024 | 20 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 16 Aug 2024 | 16 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Aug 2024 | 12 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 06 Aug 2024 | 06 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA EXPANDS JEMPERLI APPROVAL | 02 Aug 2024 | 02 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Aug 2024 | 01 Aug 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 2ND QUARTER RESULTS | 31 Jul 2024 | 31 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 29 Jul 2024 | 29 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK | 29 Jul 2024 | 29 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLENREP EMA FILING ACCEPTANCE | 19 Jul 2024 | 19 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Jul 2024 | 18 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Jul 2024 | 16 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Jul 2024 | 15 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Jul 2024 | 12 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK AND CUREVAC COLLABORATION RESTRUCTURED | 03 Jul 2024 | 03 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jul 2024 | 01 Jul 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 28 Jun 2024 | 28 Jun 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA VALIDATES JEMPERLI MARKETING AUTHORISATION | 24 Jun 2024 | 24 Jun 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS | 24 Jun 2024 | 24 Jun 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Jun 2024 | 21 Jun 2024 | 001-15170 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | 18 Jun 2024 | 31 Dec 2023 | 001-15170 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | 18 Jun 2024 | 31 Dec 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Jun 2024 | 12 Jun 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 11 Jun 2024 | 11 Jun 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 10 Jun 2024 | 10 Jun 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK | 10 Jun 2024 | 10 Jun 2024 | 001-15170 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 03 Jun 2024 | 001-15170 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Jun 2024 | 03 Jun 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE | 03 Jun 2024 | 03 Jun 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS | 03 Jun 2024 | 03 Jun 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 03 Jun 2024 | 03 Jun 2024 | 001-15170 |
| SD | Open SD document | View SEC filing for SD | SPECIALIZED DISCLOSURE REPORT | 31 May 2024 | 001-15170 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 24 May 2024 | 24 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB | 21 May 2024 | 21 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 May 2024 | 20 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CURRENT REPORT | 17 May 2024 | 17 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES SALE OF SHARES IN HALEON PLC | 17 May 2024 | 17 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 May 2024 | 14 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 13 May 2024 | 13 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 08 May 2024 | 08 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD COMMITTEE CHANGE | 08 May 2024 | 08 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 03 May 2024 | 03 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 1ST QUARTER RESULTS | 01 May 2024 | 01 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 May 2024 | 01 May 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI | 24 Apr 2024 | 24 Apr 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Apr 2024 | 19 Apr 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Apr 2024 | 17 Apr 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX | 17 Apr 2024 | 17 Apr 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS | 17 Apr 2024 | 17 Apr 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AMENDMENT - DIRECTOR/PDMR SHAREHOLDING | 16 Apr 2024 | 16 Apr 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE | 16 Apr 2024 | 16 Apr 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Apr 2024 | 15 Apr 2024 | 001-15170 |
| 6-K/A | Open 6-K/A document | View SEC filing for 6-K/A | REPLACEMENT - TOTAL VOTING RIGHTS | 04 Apr 2024 | 04 Apr 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Apr 2024 | 02 Apr 2024 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 28 Mar 2024 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 26 Mar 2024 | 26 Mar 2024 | 001-15170 |
| F-3ASR | Open F-3ASR document | View SEC filing for F-3ASR | F-3ASR | 25 Mar 2024 | 333-278205 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 25 Mar 2024 | 25 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSFER OF TREASURY SHARES | 22 Mar 2024 | 22 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Mar 2024 | 22 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NEW PHASE III JEMPERLI DATA IN ENDOMETRIAL CANCER | 18 Mar 2024 | 18 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Mar 2024 | 13 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD COMMITTEE CHANGE | 08 Mar 2024 | 08 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNOUNCES POSITIVE BLENREP DREAMM-8 RESULTS | 07 Mar 2024 | 07 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | VIIV LAI VS ORAL SOC DATA IN ADHERENCE-CHALLENGED | 06 Mar 2024 | 06 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNUAL REPORT 2023 ON FORM 20 F | 05 Mar 2024 | 05 Mar 2024 | 001-15170 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 05 Mar 2024 | 001-15170 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | 20-F | 05 Mar 2024 | 31 Dec 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING | 05 Mar 2024 | 05 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Mar 2024 | 01 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PUBLISHES ANNUAL REPORT 2023 | 01 Mar 2024 | 01 Mar 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 29 Feb 2024 | 29 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 29 Feb 2024 | 29 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 26 Feb 2024 | 26 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS | 26 Feb 2024 | 26 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Feb 2024 | 22 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED | 21 Feb 2024 | 21 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Feb 2024 | 20 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Feb 2024 | 15 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES ACQUISITION OF AIOLOS BIO | 15 Feb 2024 | 15 Feb 2024 | 001-15170 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SC 13G/A | 13 Feb 2024 | 005-84251 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Feb 2024 | 13 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Feb 2024 | 13 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Feb 2024 | 13 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Feb 2024 | 12 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Feb 2024 | 12 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Feb 2024 | 12 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN | 12 Feb 2024 | 12 Feb 2024 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO SC 13D | 09 Feb 2024 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | AMENDMENT TO FORM SC 13G | 06 Feb 2024 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | AMENDMENT TO FORM SC 13G | 06 Feb 2024 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK | 06 Feb 2024 | 06 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED | 06 Feb 2024 | 06 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA | 06 Feb 2024 | 06 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Feb 2024 | 01 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Feb 2024 | 01 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 01 Feb 2024 | 01 Feb 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL RESULTS | 31 Jan 2024 | 31 Jan 2024 | 001-15170 |
| 4 | Open 4 document | View SEC filing for 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | 30 Jan 2024 | 07 Dec 2023 | 001-37627 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK | 29 Jan 2024 | 29 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU | 29 Jan 2024 | 29 Jan 2024 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 19 Jan 2024 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Jan 2024 | 19 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Jan 2024 | 17 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CURRENT REPORT | 17 Jan 2024 | 16 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES SALE OF SHARES IN HALEON PLC | 17 Jan 2024 | 17 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Jan 2024 | 16 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA | 10 Jan 2024 | 10 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ENTERS AGREEMENT TO ACQUIRE AIOLOS BIO | 09 Jan 2024 | 09 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Jan 2024 | 02 Jan 2024 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Dec 2023 | 21 Dec 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINT | 18 Dec 2023 | 18 Dec 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Dec 2023 | 13 Dec 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTS | 12 Dec 2023 | 11 Dec 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI PLUS CHEMOTHERAPY EU AUTHORISATION | 11 Dec 2023 | 11 Dec 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PUBLISHES PROVISIONAL 2024 DIVIDEND DATES | 04 Dec 2023 | 04 Dec 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Dec 2023 | 01 Dec 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING APPLICATION | 30 Nov 2023 | 30 Nov 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 29 Nov 2023 | 29 Nov 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS | 27 Nov 2023 | 27 Nov 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Nov 2023 | 21 Nov 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 15 Nov 2023 | 15 Nov 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Nov 2023 | 13 Nov 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK RECEIVES POSITIVE CHMP OPINION FOR MOMELOTINIB | 13 Nov 2023 | 13 Nov 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Nov 2023 | 01 Nov 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 3RD QUARTER RESULTS | 01 Nov 2023 | 01 Nov 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI TRIAL MEETS OVERALL SURVIVAL ENDPOINT | 30 Oct 2023 | 30 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NMPA APPROVES VOCABRIA+REKAMBYS IN CHINA | 26 Oct 2023 | 26 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 25 Oct 2023 | 25 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NEW DATA FOR AREXVY, GSK'S RSV VACCINE | 25 Oct 2023 | 25 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Oct 2023 | 20 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Oct 2023 | 18 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Oct 2023 | 17 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINION | 16 Oct 2023 | 16 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Oct 2023 | 13 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Oct 2023 | 12 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ZANTAC (RANITIDINE) LITIGATION | 11 Oct 2023 | 11 Oct 2023 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 10 Oct 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP | 10 Oct 2023 | 10 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CURRENT REPORT | 06 Oct 2023 | 06 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES SALE OF SHARES IN HALEON PLC | 06 Oct 2023 | 06 Oct 2023 | 001-15170 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 02 Oct 2023 | 001-15170 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Oct 2023 | 02 Oct 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 27 Sep 2023 | 27 Sep 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK RSV VACCINE FOR OLDER ADULTS APPROVED IN JAPAN | 25 Sep 2023 | 25 Sep 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Sep 2023 | 21 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | APRETUDE FOR PREP RECEIVES EMA APPROVAL | 19 Sep 2023 | 19 Sep 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA APPROVES OJJAARA (MOMELOTINIB) | 18 Sep 2023 | 18 Sep 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Sep 2023 | 13 Sep 2023 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 11 Sep 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Sep 2023 | 11 Sep 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | MOMELOTINIB FILING ACCEPTED IN JAPAN | 11 Sep 2023 | 11 Sep 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Sep 2023 | 06 Sep 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Sep 2023 | 01 Sep 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK'S NUCALA CRSWNP SUBMISSION ACCEPTED IN JAPAN | 01 Sep 2023 | 01 Sep 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 31 Aug 2023 | 31 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 31 Aug 2023 | 31 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 25 Aug 2023 | 25 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Aug 2023 | 23 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SHINGRIX DATA DEMONSTRATE 100% EFFICACY IN CHINA | 23 Aug 2023 | 23 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Aug 2023 | 22 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Aug 2023 | 10 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 Aug 2023 | 09 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Aug 2023 | 01 Aug 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA APPROVES NEW USE FOR JEMPERLI PLUS CHEMO | 31 Jul 2023 | 31 Jul 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 31 Jul 2023 | 31 Jul 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 28 Jul 2023 | 28 Jul 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 2ND QUARTER RESULTS | 26 Jul 2023 | 26 Jul 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CABOTEGRAVIR LA FOR PREP RECEIVES POSITIVE CHMP | 24 Jul 2023 | 24 Jul 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Jul 2023 | 20 Jul 2023 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 20 Jul 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Jul 2023 | 17 Jul 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Jul 2023 | 13 Jul 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Jul 2023 | 03 Jul 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES ACQUISITION OF BELLUS HEALTH | 28 Jun 2023 | 28 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATE | 27 Jun 2023 | 27 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINION | 26 Jun 2023 | 26 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVER | 26 Jun 2023 | 26 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Jun 2023 | 23 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Jun 2023 | 23 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Jun 2023 | 23 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 23 Jun 2023 | 23 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSKS AREXVY RECOMMENDED BY ACIP | 22 Jun 2023 | 22 Jun 2023 | 001-15170 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT | 21 Jun 2023 | 31 Dec 2022 | 001-15170 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | 21 Jun 2023 | 31 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINE | 21 Jun 2023 | 21 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIB | 16 Jun 2023 | 16 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Jun 2023 | 12 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EU AUTHORISATION OF GSKS RSV VACCINE AREXVY | 07 Jun 2023 | 07 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLI | 06 Jun 2023 | 06 Jun 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jun 2023 | 01 Jun 2023 | 001-15170 |
| SD | Open SD document | View SEC filing for SD | SPECIALIZED DISCLOSURE | 30 May 2023 | 001-15170 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 May 2023 | 22 May 2023 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 16 May 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 May 2023 | 15 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 15 May 2023 | 15 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 May 2023 | 12 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | MENABCWY VACCINE PRELIMINARY PHASE III RESULTS | 12 May 2023 | 12 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC LITIGATION UPDATE BC CANADA | 12 May 2023 | 12 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES SALE OF SHARES IN HALEON PLC | 12 May 2023 | 12 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CURRENT REPORT OF FOREIGN ISSUER | 12 May 2023 | 11 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 May 2023 | 09 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 04 May 2023 | 04 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 03 May 2023 | 03 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA APPROVES GSKS RSV VACCINE FOR OLDER ADULTS | 03 May 2023 | 03 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 May 2023 | 02 May 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 28 Apr 2023 | 28 Apr 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK RSV OA VACCINE GAINS POSITIVE EMA CHMP OPINION | 27 Apr 2023 | 27 Apr 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 1ST QUARTER RESULTS | 26 Apr 2023 | 26 Apr 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA VALIDATES JEMPERLI FILING FOR NEW INDICATION | 25 Apr 2023 | 25 Apr 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Apr 2023 | 20 Apr 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Apr 2023 | 19 Apr 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK REACHES AGREEMENT TO ACQUIRE BELLUS HEALTH INC | 18 Apr 2023 | 18 Apr 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Apr 2023 | 17 Apr 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GEPOTIDACIN POSITIVE PHASE III DATA | 17 Apr 2023 | 17 Apr 2023 | 001-15170 |
| 20-F/A | Open 20-F/A document | Open XBRL data | View SEC filing for 20-F/A | 20-F/A | 17 Apr 2023 | 31 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Apr 2023 | 03 Apr 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE PHASE III RUBY RESULTS FOR JEMPERLI | 28 Mar 2023 | 28 Mar 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | PUBLICATION OF 2023 AGM NOTICE | 27 Mar 2023 | 27 Mar 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 24 Mar 2023 | 24 Mar 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Mar 2023 | 21 Mar 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Mar 2023 | 20 Mar 2023 | 001-15170 |
| EFFECT | Open EFFECT document | View SEC filing for EFFECT | 15 Mar 2023 | 333-254756 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE | 14 Mar 2023 | 14 Mar 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NUCALA NDA ACCEPTED FOR REVIEW IN CHINA | 14 Mar 2023 | 14 Mar 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Mar 2023 | 13 Mar 2023 | 001-15170 |
| POS AM | Open POS AM document | View SEC filing for POS AM | POS AM | 10 Mar 2023 | 333-254756 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNUAL REPORT 2022 ON FORM 20-F | 10 Mar 2023 | 10 Mar 2023 | 001-15170 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 10 Mar 2023 | 001-15170 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | 20-F | 10 Mar 2023 | 31 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PUBLISHES ANNUAL REPORT 2022 | 10 Mar 2023 | 10 Mar 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE | 02 Mar 2023 | 02 Mar 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Mar 2023 | 01 Mar 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 27 Feb 2023 | 27 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Feb 2023 | 23 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA | 23 Feb 2023 | 23 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Feb 2023 | 22 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL | 16 Feb 2023 | 16 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Feb 2023 | 15 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Feb 2023 | 15 Feb 2023 | 001-15170 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SC 13G/A | 14 Feb 2023 | 005-84251 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Feb 2023 | 14 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Feb 2023 | 14 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Feb 2023 | 14 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Feb 2023 | 14 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Feb 2023 | 10 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL | 10 Feb 2023 | 10 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI FDA ODAC POSITIVE OUTCOME | 10 Feb 2023 | 10 Feb 2023 | 001-15170 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SCHEDULE 13G | 06 Feb 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD | 02 Feb 2023 | 02 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Feb 2023 | 01 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Feb 2023 | 01 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA | 01 Feb 2023 | 01 Feb 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL RESULTS | 01 Feb 2023 | 01 Feb 2023 | 001-15170 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SCHEDULE 13G | 30 Jan 2023 | ||
| 3 | Open 3 document | View SEC filing for 3 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP | 30 Jan 2023 | 23 Jan 2023 | 001-37627 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 20 Jan 2023 | ||
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | SCHEDULE 13D/A | 20 Jan 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Jan 2023 | 18 Jan 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Jan 2023 | 17 Jan 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Jan 2023 | 17 Jan 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Jan 2023 | 13 Jan 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Jan 2023 | 12 Jan 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Jan 2023 | 03 Jan 2023 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Dec 2022 | 22 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Dec 2022 | 21 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Dec 2022 | 21 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD AND COMMITTEE CHANGES | 15 Dec 2022 | 15 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Dec 2022 | 13 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 07 Dec 2022 | 07 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSFER OF TREASURY SHARES | 05 Dec 2022 | 05 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 02 Dec 2022 | 02 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER | 02 Dec 2022 | 02 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA FILE ACCEPTED FOR MOMELOTINIB | 02 Dec 2022 | 02 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Dec 2022 | 01 Dec 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATES | 25 Nov 2022 | 25 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLENREP US UPDATE | 22 Nov 2022 | 22 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Nov 2022 | 21 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 15 Nov 2022 | 15 Nov 2022 | 001-15170 |
| 3 | Open 3 document | View SEC filing for 3 | 14 Nov 2022 | 07 Nov 2022 | 001-38266 | |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | SCHEDULE 13D/A | 14 Nov 2022 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK UPDATE: ZEJULA 2L IN US | 14 Nov 2022 | 14 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU | 10 Nov 2022 | 10 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Nov 2022 | 10 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING APPLICATION | 10 Nov 2022 | 10 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DREAMM-3 PHASE III TRIAL FOR BLENREP | 07 Nov 2022 | 07 Nov 2022 | 001-15170 |
| 3 | Open 3 document | View SEC filing for 3 | ME - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP | 04 Nov 2022 | 16 Jun 2021 | 001-39587 |
| SC 13D | Open SC 13D document | View SEC filing for SC 13D | ACQUISITION OF BENEFICIAL OWNERSHIP | 04 Nov 2022 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP | 03 Nov 2022 | 03 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 3RD QUARTER RESULTS | 02 Nov 2022 | 02 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK RSV VACCINE: US FDA PRIORITY REVIEW | 02 Nov 2022 | 02 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Nov 2022 | 01 Nov 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEW | 28 Oct 2022 | 28 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREP | 28 Oct 2022 | 28 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNOUNCES FDA MEETING OUTCOME ON DAPRODUSTAT | 27 Oct 2022 | 27 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE | 27 Oct 2022 | 27 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD COMMITTEE CHANGES | 25 Oct 2022 | 25 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RSV OLDER ADULT VACCINE SUBMISSION IN JAPAN | 21 Oct 2022 | 21 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | MENVEO NEW SINGLE-VIAL APPROVED BY US FDA | 17 Oct 2022 | 17 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Oct 2022 | 14 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Oct 2022 | 13 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Oct 2022 | 13 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Oct 2022 | 13 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINE | 13 Oct 2022 | 13 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Oct 2022 | 12 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATION | 11 Oct 2022 | 11 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 07 Oct 2022 | 07 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 07 Oct 2022 | 07 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Oct 2022 | 03 Oct 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 30 Sep 2022 | 30 Sep 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 26 Sep 2022 | 26 Sep 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK CHIEF FINANCIAL OFFICER SUCCESSION | 26 Sep 2022 | 26 Sep 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIAL | 22 Sep 2022 | 22 Sep 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEM | 22 Sep 2022 | 22 Sep 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Sep 2022 | 21 Sep 2022 | 001-15170 |
| 4 | Open 4 document | View SEC filing for 4 | 20 Sep 2022 | 16 Sep 2022 | 001-36033 | |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 20 Sep 2022 | ||
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 15 Sep 2022 | 001-15170 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Sep 2022 | 13 Sep 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 Sep 2022 | 08 Sep 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTAT | 06 Sep 2022 | 06 Sep 2022 | 001-15170 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 01 Sep 2022 | 001-15170 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Sep 2022 | 01 Sep 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK BOARD CHANGES | 24 Aug 2022 | 24 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Aug 2022 | 22 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA NEW DRUG APPLICATION FILE ACCEPTANCE FOR MMB | 17 Aug 2022 | 17 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION UPDATE | 17 Aug 2022 | 17 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES ACQUISITION OF AFFINIVAX, INC. | 16 Aug 2022 | 16 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | 12 Aug 2022 | 12 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Aug 2022 | 11 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Aug 2022 | 10 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CURRENT REPORT OF FOREIGN ISSUER | 03 Aug 2022 | 03 Aug 2022 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 03 Aug 2022 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Aug 2022 | 01 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Aug 2022 | 01 Aug 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 29 Jul 2022 | 29 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK BOARD CHANGE | 29 Jul 2022 | 29 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 28 Jul 2022 | 28 Jul 2022 | 001-15170 |
| SC 13D | Open SC 13D document | View SEC filing for SC 13D | SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP | 27 Jul 2022 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | 2ND QUARTER RESULTS | 27 Jul 2022 | 27 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 22 Jul 2022 | 22 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD AND COMMITTEE CHANGES | 22 Jul 2022 | 22 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | COMPLETION OF GSK SHARE CONSOLIDATION | 18 Jul 2022 | 18 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HALEON DEMERGER COMPLETION AND SHARE CONSOLIDATION | 18 Jul 2022 | 18 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Jul 2022 | 12 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 Jul 2022 | 08 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 Jul 2022 | 08 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 Jul 2022 | 08 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 Jul 2022 | 08 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 Jul 2022 | 08 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF GENERAL MEETING | 06 Jul 2022 | 06 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Jul 2022 | 06 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK DISCLOSE DISCONTINUED OPERATIONS FROM Q2 2022 | 05 Jul 2022 | 05 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 05 Jul 2022 | 05 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 05 Jul 2022 | 05 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jul 2022 | 01 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK COMPLETES ACQUISITION OF SIERRA ONCOLOGY | 01 Jul 2022 | 01 Jul 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 28 Jun 2022 | 28 Jun 2022 | 001-15170 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | 28 Jun 2022 | 31 Dec 2021 | 001-15170 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | 28 Jun 2022 | 31 Dec 2021 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK FILES SHINGRIX 18+ AT RISK INDICATION IN JAPAN | 28 Jun 2022 | 28 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 27 Jun 2022 | 27 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 24 Jun 2022 | 24 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Jun 2022 | 16 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE PHASE III DATA FOR GSK'S RSV OA VACCINE | 10 Jun 2022 | 10 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 Jun 2022 | 09 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 07 Jun 2022 | 07 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA APPROVAL OF PRIORIX | 06 Jun 2022 | 06 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 6-K | 01 Jun 2022 | 01 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DEMERGER UPDATE: PUBLICATION OF DOCUMENTS | 01 Jun 2022 | 01 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DEMERGER UPDATE: SUBMISSION OF DOCUMENTS TO FCA | 01 Jun 2022 | 01 Jun 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK TO ACQUIRE AFFINIVAX, INC. | 31 May 2022 | 31 May 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FURTHER APPOINTMENTS TO DESIGNATE HALEON BOARD | 31 May 2022 | 31 May 2022 | 001-15170 |
| SD | Open SD document | View SEC filing for SD | SPECIALIZED DISCLOSURE | 27 May 2022 | 001-15170 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK CERVARIX TWO-DOSE SCHEDULE APPROVED BY NMPA | 27 May 2022 | 26 May 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 25 May 2022 | 25 May 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 23 May 2022 | 23 May 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IAIN MACKAY - EXTERNAL APPOINTMENT | 19 May 2022 | 19 May 2022 | 001-15170 |
| 424B3 | Open 424B3 document | View SEC filing for 424B3 | 424B3 | 17 May 2022 | 333-264759 | |
| 424B3 | Open 424B3 document | View SEC filing for 424B3 | 424B3 | 17 May 2022 | 333-232726 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | CHANGE OF NAME TO GSK PLC | 16 May 2022 | 16 May 2022 | 001-15170 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 13 May 2022 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 May 2022 | 13 May 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 May 2022 | 12 May 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 11 May 2022 | 11 May 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 May 2022 | 09 May 2022 | 001-15170 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 09 May 2022 | 001-15170 | ||
| F-6EF | Open F-6EF document | View SEC filing for F-6EF | F-6 | 06 May 2022 | 333-264759 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 04 May 2022 | 04 May 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 04 May 2022 | 04 May 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 May 2022 | 03 May 2022 | 001-15170 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 02 May 2022 | 001-15170 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | 1ST QUARTER RESULTS | 27 Apr 2022 | 27 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 26 Apr 2022 | 26 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDA | 19 Apr 2022 | 19 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Apr 2022 | 14 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Apr 2022 | 14 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Apr 2022 | 14 Apr 2022 | 001-15170 |
| DFAN14A | Open DFAN14A document | View SEC filing for DFAN14A | DFAN14A | 13 Apr 2022 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Apr 2022 | 13 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Apr 2022 | 13 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK AGREES TO ACQUIRE SIERRA ONCOLOGY FOR $1.9BN | 13 Apr 2022 | 13 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Apr 2022 | 12 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Apr 2022 | 12 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Apr 2022 | 12 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Apr 2022 | 12 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Apr 2022 | 01 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES | 01 Apr 2022 | 01 Apr 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | PUBLICATION OF 2022 AGM NOTICE | 28 Mar 2022 | 28 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 24 Mar 2022 | 24 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONAL | 24 Mar 2022 | 24 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Mar 2022 | 23 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ISSUANCE OF NOTES | 23 Mar 2022 | 23 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Mar 2022 | 16 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Mar 2022 | 15 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | APPOINTMENTS TO DESIGNATE HALEON BOARD | 15 Mar 2022 | 15 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Mar 2022 | 11 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 Mar 2022 | 09 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNUAL REPORT 2021 ON FORM 20-F | 08 Mar 2022 | 08 Mar 2022 | 001-15170 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 08 Mar 2022 | 001-15170 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | 20-F | 08 Mar 2022 | 31 Dec 2021 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK PUBLISHES ANNUAL REPORT 2021 | 04 Mar 2022 | 04 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Mar 2022 | 01 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Mar 2022 | 01 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Mar 2022 | 01 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY EMA | 01 Mar 2022 | 01 Mar 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FOMR 6-K | 28 Feb 2022 | 28 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 28 Feb 2022 | 28 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 24 Feb 2022 | 24 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CANADA APPROVAL FOR MEDICAGO GSK COVID-19 VACCINE | 24 Feb 2022 | 24 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Feb 2022 | 23 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Feb 2022 | 22 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK CONSUMER HEALTHCARE TO BE CALLED HALEON | 22 Feb 2022 | 22 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Feb 2022 | 18 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK GIVES UPDATE ON RSV MATERNAL VACCINE CANDIDATE | 18 Feb 2022 | 18 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2022 | 17 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2022 | 17 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2022 | 17 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2022 | 17 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Feb 2022 | 17 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Feb 2022 | 16 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Feb 2022 | 14 Feb 2022 | 001-15170 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SC 13G | 14 Feb 2022 | 005-84251 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSFER OF TREASURY SHARES | 14 Feb 2022 | 14 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Feb 2022 | 11 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Feb 2022 | 11 Feb 2022 | 001-15170 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | AMENDMENT TO SC 13G | 10 Feb 2022 | ||
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SCHEDULE 13G | 10 Feb 2022 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | AMENDMENT TO SC 13G | 10 Feb 2022 | ||
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | AMENDMENT TO FORM SC 13D | 10 Feb 2022 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | AMENDMENT TO FORM SC 13G | 10 Feb 2022 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITIS | 10 Feb 2022 | 10 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL RESULTS | 09 Feb 2022 | 09 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 Feb 2022 | 09 Feb 2022 | 001-15170 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | 07 Feb 2022 | 005-84251 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | PUBLICATION OF FULL YEAR 2021 RESULTS | 07 Feb 2022 | 07 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GSK ANNOUNCES SETTLEMENT BETWEEN VIIV AND GILEAD | 02 Feb 2022 | 02 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA APPROVES VIIV HEALTHCARE'S SNDA FOR CABENUVA | 01 Feb 2022 | 01 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Feb 2022 | 01 Feb 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 26 Jan 2022 | 26 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Jan 2022 | 20 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Jan 2022 | 19 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Jan 2022 | 19 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Jan 2022 | 19 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TONY WOOD APPOINTED CSO DESIGNATE, GSK | 19 Jan 2022 | 19 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Jan 2022 | 18 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Jan 2022 | 18 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE - GSK CONSUMER HEALTHCARE | 18 Jan 2022 | 18 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Jan 2022 | 14 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Jan 2022 | 13 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Jan 2022 | 11 Jan 2022 | 001-15170 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US GOVT BUYS ADDITIONAL 600,000 SOTROVIMAB DOSES | 11 Jan 2022 | 11 Jan 2022 | 001-15170 |
About this filer
GSK plc files with the SEC under CIK 0001131399. This page aggregates EDGAR filings and related ownership activity.
Industry: Pharmaceutical Preparations.
FAQ
- What is a CIK?
- A Central Index Key (CIK) is a unique identifier assigned by the SEC to each filer.
- Why are some filings missing?
- New filings appear as the SEC updates EDGAR, and older records can vary by availability.
- How often is this page updated?
- Updates follow new EDGAR submissions and periodic data refreshes.